Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy
Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clinical Gastroenterology And Hepatology 2016, 15: 746-755.e4. PMID: 27847278, PMCID: PMC5823259, DOI: 10.1016/j.cgh.2016.10.036.Peer-Reviewed Original ResearchConceptsLiver Cancer staging systemIntra-arterial therapyCancer (AJCC) staging systemHong Kong Liver Cancer (HKLC) staging systemStaging systemHepatocellular carcinomaSurvival timeBCLC systemPatient survival timeHKLC systemRetrospective analysisBarcelona Clinic Liver Cancer (BCLC) staging systemStage IVUnresectable hepatocellular carcinomaOverall survival timeKaplan-Meier estimatesDate of deathHepatitis CSystemic chemotherapyHepatitis BMost patientsUnresectable tumorsEntire cohortC-statisticHCC stage